Skip to main content
Equibles
DSGN logo

DSGN · Design Therapeutics, Inc. · Metrics

Track DSGN — free

Use DSGN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research DSGN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$11.17 +0.53 (+4.98%)
Russell 2000 member Rebalance outlook locked
Market Cap
$665.87M
Shares
62.58M
Volume · Oct 20 204.83K Avg daily vol (3M) 599.69K

DSGN metrics

69 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$10.64
Market cap
$665.87M

Price action

20 metrics
Price change (1W)
-2.5%
Price change (30D)
-15.2%
Price change (3M)
-10.4%
Price change (6M)
-19.1%
Price change (YTD)
+13.4%
Price change (1Y)
+85.4%
Trailing year
Price change (5Y)
-23.5%
52-week high
$15.94
52-week low
$5.53
Change from 52-week high
-33.2%
Change from 52-week low
+92.4%
Annualized volatility
73.9%
Annualized volatility (3M)
53.4%
Beta
1.2
RSI (14D)
37.0
Price vs SMA 50
-20.7%
Price vs SMA 200
-12.1%
Avg volume (3M)
599,692
Relative volume
0.6
Average dollar volume
$7.90M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
62.58M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
3.3
reciprocal yield 30.3%
FCF yield
-8.3%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-10.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-04-28

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$79.36M
Net income (TTM)
−$70.80M
Trailing 12 months
Diluted EPS (TTM)
$-1.18
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-1.32
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-1.18
Operating cash flow per diluted share (TTM)
$-0.92
Free cash flow per diluted share (TTM)
$-0.92
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$0.98
Stock compensation per diluted share (TTM)
$0.25
Book value per share
$3.52

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+9.9%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-35.1%
Return on assets
-32.9%
Debt / equity
0.0
Current ratio
18.9
EBITDA (TTM)
—
Free cash flow (TTM)
−$55.14M
Quick ratio
18.9
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$207.40M
Latest balance sheet
Cash & equivalents
$12.91M
Total assets
$215.13M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$55.08M
Capital expenditures (TTM)
$55,000
R&D (TTM)
$58.78M
SG&A (TTM)
—
Stock compensation (TTM)
$14.82M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
136
13F filer change QoQ
+11
Institutional ownership
71.7%
Conviction holders (share of 13F filers)
4.8%
Crowding (high-turnover and private-fund holders)
47.5%
Private-fund adviser ownership
47.5%
Active holders' share change QoQ
+3.0%
Holder tenure
4.5
Price vs estimated holder cost
-16.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
7.5%

Short interest

3 metrics
Short interest
10.6%
Latest settlement · 8.7 days to cover
Days to cover
8.7d
Short-squeeze score
72 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1807120 CUSIP 25056L103 13F (30d) 9 filings 9 filers Visit website Investor relations